Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392156 · ClinicalTrials.gov registry record
Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
A clinical trial, sponsored by Bioverativ Therapeutics.
- Terminated
- Registry status
- 3
- Enrollment target
NCT02392156: Clinical Trial study, sponsored by Bioverativ Therapeutics.
NCT02392156 is a clinical trial that was terminated before completion, run by Bioverativ Therapeutics. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02392156 was terminated before completion, sponsored by Bioverativ Therapeutics.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effectiveness of prophylactic treatment with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes while maintaining disease control in males with hemophilia A or B.
Interventions
- BIOLOGICAL rFVIIIFc
- BIOLOGICAL rFIXFc
- DRUG non-Fc FVIII replacement products
- DRUG non-Fc FIX replacement products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-12 |
Why NCT02392156 stopped before completion
NCT02392156 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which rFVIIIFc is the first listed.
NCT02392156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02392156 about?
NCT02392156 is a clinical study titled "Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes". The primary objective of the study is to evaluate the effectiveness of prophylactic treatment with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes while maintaining ...
What is the current status of trial NCT02392156?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2015-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02392156?
The interventions under investigation include: rFVIIIFc (BIOLOGICAL), rFIXFc (BIOLOGICAL), non-Fc FVIII replacement products (DRUG), non-Fc FIX replacement products (DRUG).
Who is sponsoring clinical trial NCT02392156?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia